AI Article Synopsis
- A recent study using SPECT on rats found that haloperidol, an antipsychotic, may increase dopamine release enough to affect binding to the dopamine transporter.
- Researchers aimed to replicate this finding using storage phosphor imaging on rats treated with either saline or haloperidol before a (123)I-FP-CIT injection.
- The results showed that haloperidol did not significantly alter binding ratios in the brain regions assessed, indicating that changes in dopamine levels from acute haloperidol administration were not observable with the imaging technique used.
Article Abstract
Unlabelled: A recent (123)I-FP-CIT ((123)-I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane) SPECT study on rats suggested that a single 1 mg/kg dose of the antipsychotic haloperidol induces enough dopamine release to compete with (123)I-FP-CIT for binding to the dopamine transporter. Taking into account the far-reaching consequences of this proposition, we were interested in testing whether we could reproduce this finding using storage phosphor imaging.
Methods: Twenty rats were pretreated with saline or haloperidol (1 mg/kg of body weight) and then injected with (123)I-FP-CIT. Two hours after (123)I-FP-CIT injection, the rats were sacrificed and binding in the striatum, nucleus accumbens, and cerebellum (nonspecific binding) was measured.
Results: In contrast to the earlier SPECT finding, acute administration of haloperidol did not induce a significant change in (123)I-FP-CIT binding ratios in the striatum and nucleus accumbens.
Conclusion: Changes in synaptic dopamine due to acute haloperidol administration were not detectable with (123)I-FP-CIT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.113.132340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the relation between REM sleep behavior disorder onset and striatal dopaminergic dysfunction in Parkinson's Disease.
J Neurol
December 2024
Department "G.F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Background: The α-Synuclein Origin and Connectome (SOC) model recently proposed two different Parkinson's Disease (PD) phenotypes clinically based on the relationship between REM sleep behavior disorder (RBD) and motor symptoms' onset: a "body first" phenotype and a "brain first" phenotype in which RBD precedes or may follow the motor onset, respectively. A higher burden of non-motor symptoms as well as a more symmetrical clinical presentation have also been predicted in the body-first phenotype. This point has been poorly assessed through semi-quantitative striatal dopaminergic functional imaging to date.
View Article and Find Full Text PDFReliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Purpose: This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT.
Methods: 43 patients (70.7 ± 8.
Optimal DaTQUANT Thresholds for Diagnostic Accuracy of Dementia with Lewy Bodies (DLB) and Parkinson's Disease (PD).
Tomography
October 2024
Statistics Consulting Laboratory, BIO5 Institute, University of Arizona, Tucson, AZ 85719, USA.
Quantitative thresholds are helpful to define an abnormal DaT SPECT in patients with suspected nigrostriatal degenerative diseases (NSDD). The optimal DaTQUANT threshold for diagnostic accuracy of DaT SPECT across combined movement and cognitive disorder populations has been previously described. : We established optimal DaTQUANT thresholds that enhance the discrimination between dementia with Lewy bodies (DLB) and non-DLB dementia types, as well as between Parkinsonian syndromes (PS) and conditions not characterized by nigrostriatal degeneration (non-PS).
View Article and Find Full Text PDFInsular monoaminergic deficits in prodromal α-synucleinopathies.
Ann Clin Transl Neurol
November 2024
Sleep Medicine Centre, Neurology Unit, University Hospital of Rome Tor Vergata, 00133, Italy.
Methods: This study assessed data from two cohorts of patients with alpha-synucleinopathies (University of Brescia and University of Rome Tor-Vergata cohorts). Consecutive participants with video-polysomnography-confirmed iRBD, Parkinson's disease (PD), dementia with Lewy bodies (DLB) and controls underwent neurological, clinical and I-FP-CIT SPECT imaging assessments. Individuals with iRBD were longitudinally monitored to collect clinical phenoconversion to PD or DLB.
View Article and Find Full Text PDFProminent loss of striatal dopamine transporter binding in frontotemporal lobar degeneration with the MAPT N279K mutation present as early as at prodromal stage without parkinsonism.
Parkinsonism Relat Disord
November 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Our research found out, from I-FP-CIT SPECT scans of three familial frontotemporal dementia (fFTD) individuals with MAPT N279K mutation and similar autopsy findings of frontotemporal degeneration with severe neuronal loss in the substantia nigra, that prominent decrease of dopamine transporter binding (z-score < -5.0) was present at prodromal fFTD without parkinsonism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!